[Compounds with potential antitumor activity. V. 2-Substituted 3-[2-(1,3,4-thiadazolyl)]-4-thiazolidinone].
The synthesis of a series of 2-substituted 3-[2-(1,3,4-thiadiazolyl)]-4-thiazolidinones is described. Evaluation of these derivatives against P 388 lymphocytic leukemia growth in mice revealed that no compound shows significant activity. 2-(2-Thienyl)-3-[2-(1,3,4-thiadiazolyl)]-4-thiazolidinone (I) whose significant activity on P 388 leukemia was reported in a previous paper, was tested against other experimental tumors: it exhibits slight activity also against L 1210 leukemia and M 5076 ascitic sarcoma.
D000818:Animals; D000970:Antineoplastic Agents / Q000138:chemical synthesis*; D007939:Leukemia L1210 / Q000188:drug therapy; D007941:Leukemia P388 / Q000188:drug therapy; D051379:Mice; D012513:Sarcoma, Experimental / Q000188:drug therapy; D013830:Thiadiazoles / Q000138:chemical synthesis* / Q000494:pharmacology; D013844:Thiazoles / Q000138:chemical synthesis* / Q000494:pharmacology
D000970:Antineoplastic Agents; D013830:Thiadiazoles; D013844:Thiazoles
Composti a presumibile attività antitumorale. Nota V--3-[2-(1,3,4-Tiadiazolil)]-4-tiazolidinoni 2-sostituiti.